5.4 Corticosteroids in Liver Transplant

Corticosteroids in Liver Transplantation

Comprehensive Lecture Summary

Speaker: Prof. Sanjaya Satapathy, MD, FAASLD

Module: 5.4 – Transplant Immunosuppression Series

1. Main Clinical Topics Discussed

• Mechanism of action of corticosteroids in transplant immunology
• Clinical use of corticosteroids in liver transplantation (induction, maintenance, rejection treatment)
• Management of steroid-resistant acute cellular rejection
• Major corticosteroid-related complications in the post-transplant setting
• Steroid minimization and withdrawal strategies
• HCC-specific immunosuppression considerations

2. Key Learning Points, Guidelines, and Recommendations

Mechanism of Action

• Corticosteroids suppress immune responses through broad, non-selective inhibition of inflammatory cytokines, including:

- Interleukin-1 (IL-1)

- Interleukin-2 (IL-2)

- Tumor necrosis factor-alpha (TNF-α)

• Result: Reduced T-cell activation and proliferation, dampening of allograft rejection responses
• Unlike calcineurin inhibitors (CNIs), steroids are non-selective — they suppress multiple immune pathways simultaneously, explaining both their efficacy and broad toxicity profile

Clinical Use in Liver Transplantation

Induction/Perioperative:

• Standard practice: IV methylprednisolone ~500 mg intraoperatively at time of transplant
• Provides immediate immunosuppression during peak immune activation when the graft is introduced

Post-Transplant Taper:

• Steroids tapered over the first days to weeks post-operatively
• Most modern transplant programs target complete steroid withdrawal by 3–6 months post-transplant in uncomplicated patients
• Long-term chronic high-dose steroids are not standard in contemporary liver transplant protocols

Exceptions requiring longer steroid courses:

• Recurrent autoimmune liver disease (e.g., autoimmune hepatitis)
• Ongoing or recurrent rejection episodes
• Other significant clinical complications

Treatment of Acute Cellular Rejection (ACR)

• First-line therapy: Pulse-dose IV methylprednisolone for approximately 3 days, followed by gradual taper (~500 mg doses)
• Indicated for biopsy-confirmed mild-to-moderate ACR — rejection must not be treated empirically without histologic confirmation
• Many patients respond without requiring escalation to additional agents

Steroid-Resistant Rejection

When ACR fails to respond to pulse steroids:

1. Optimize CNI exposure — increase tacrolimus to therapeutic target (trough ~8–10 ng/mL)

2. Add or optimize mycophenolate mofetil (MMF) — enhances T-cell proliferation suppression

3. Anti-thymocyte globulin (ATG) — reserved for severe or refractory cases; provides potent T-cell depletion

3. Specific Clinical Data, Statistics, and Study Results Cited

• No specific randomized controlled trials or named studies were cited in this lecture
• Key clinical benchmarks referenced:

- Steroid withdrawal target: 3–6 months post-transplant in eligible patients

- Tacrolimus therapeutic trough range in rejection management: 8–10 ng/mL

- Pulse steroid dosing for ACR: ~500 mg IV methylprednisolone × 3 days

- Intraoperative induction dose: ~500 mg IV methylprednisolone

4. Practical Takeaways for Clinicians

Metabolic & Endocrine Complications

• Post-transplant hyperglycemia is multifactorial:

- Corticosteroids → increased insulin resistance and hepatic glucose production

- Tacrolimus → impaired pancreatic β-cell insulin secretion

- Physiologic surgical stress response

- Management: Insulin is preferred initial therapy for flexibility and rapid titration

- New-onset diabetes after transplant (NODAT) most commonly attributed to tacrolimus + steroid combination

Infectious Risk

-